Pharmaceutical Benefits Scheme Drug Listings

Follow the links below to find information about the listing of drugs on the Pharmaceutical Benefits Scheme (PBS).

Reviewed March 2011

Printer friendly page Printer friendly page

19 Resources Found

Results 1 to 19 displayed.

Title:   Erbitux, Gilenya and Other Medicines Listed on the PBS
Publisher:   HealthInsite Editorial Team
Description:   More than 400,000 Australians will benefit from new subsidised medicines from 1 September 2011, including patients suffering multiple sclerosis, cystic fibrosis and various forms of cancer.
Date:   Sep 2011
Title:   Media release. Erbitux, Gilenya and other medicines listed on the PBS
Publisher:   Australian Government Department of Health and Ageing
Description:   More than 400,000 Australians will benefit from new subsidised medicines from 1 September 2011, including patients suffering multiple sclerosis, cystic fibrosis and various forms of cancer.
Date:   Sep 2011
Title:   New Medicines Listed on the PBS
Publisher:   HealthInsite Editorial Team
Description:   More than 400,000 Australians will benefit from new subsidised medicines from 1 September 2011, including patients suffering multiple sclerosis, cystic fibrosis and various forms of cancer.
Date:   Jun 2011
Title:   Media release. Erbitux and other new medicines listed on the PBS
Publisher:   Australian Government Department of Health and Ageing
Description:   More than 400,000 Australians will benefit from new subsidised medicines from 1 September 2011, including patients suffering multiple sclerosis, cystic fibrosis and various forms of cancer.
Date:   Jun 2011
Title:   Pharmaceutical Benefits Scheme cost recovery
Publisher:   Australian Prescriber
Description:   Since the beginning of 2010 the Australian Government has applied cost recovery to the listing process of the Pharmaceutical Benefits Scheme (PBS). Drug companies seeking to list their drugs on the PBS or vaccines on the National Immunisation Program pay a fee at two key points – upon lodgement of the application and at the pricing stage.
Date:   Jun 2011
Title:   New medicines to be listed on the PBS
Publisher:   HealthInsite Editorial Team
Description:   Australians suffering from serious and often life-threatening diseases will benefit from five new medicines and vaccines being listed with the Pharmaceutical Benefits Scheme from 1 April 2011, and two additional ones being listed from 1 May 2011.
Date:   Mar 2011
Title:   Your questions to the PBAC: Enoxaparin for haemodialysis - authority indications
Publisher:   Australian Prescriber
Description:   Patients on haemodialysis are able to receive double the normal quantity of enoxaparin (Clexane) solution for injection per prescription - that is, 20 ampoules and 3 repeats versus the usual 10 ampoules. However, the restricted benefit listing for haemodialysis only covers the 20, 40 and 60 mg strengths.
Date:   Feb 2011
Title:   Your questions to the PBAC: Avoiding wastage with insulin prescribing
Publisher:   Australian Prescriber
Description:   A practical and simple approach of saving is to change the PBS listing of insulin prescribed for gestational diabetes and users of low-dose insulin who will not necessarily go through the normal quantity of insulin provided to them. The standard quantity of insulin supplied by the PBS is five boxes of five individually packed units.
Date:   Oct 2010
Title:   Subsidised medicines for Aboriginal and Torres Strait Islander people
Publisher:   Australian Prescriber
Description:   Since August 2006, the Pharmaceutical Benefits Scheme (PBS) has been including new listings specifically for the treatment of common conditions in Aboriginal and Torres Strait Islander people.
Date:   Aug 2008
Title:   EpiPen and EpiPen Jr recommended for PBS listing
Publisher:   Australasian Society of Clinical Immunology and Allergy (ASCIA)
Description:   EpiPen and EpiPen Jr are pre-loaded syringes that inject a single dose of adrenaline for the emergency treatment of adults and children who experience severe and potentially life-threatening allergic reactions (anaphylaxis, or 'allergic shock').
Date:   Oct 2007
Title:   New listings for the treatment of age-related macular degeneration
Publisher:   Australian Government Department of Health and Ageing
Description:   LUCENTIS® (ranibizumab) is a new drug that will be listed on the Pharmaceutical Benefits Scheme from 1 August 2007 for the treatment of wet age related macular degeneration.
Date:   Jun 2007
Title:   PBAC: taxanes
Publisher:   Australian Prescriber
Description:   The listing of trastuzumab on the Pharmaceutical Benefits Scheme (PBS) in October 2006 was heralded with much fanfare. Along with this listing, changes to the prescribing requirements for taxanes also occurred.
Date:   Feb 2007
Title:   Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (version 4.0)
Publisher:   Australian Government Department of Health and Ageing
Description:   The Pharmaceutical Benefits Advisory Committee (PBAC) endorsed this edition of its Guidelines in November 2006. It follows an extensive consultation process and provides guidance for all stakeholders involved in or affected by submissions to the PBAC or listings on the Pharmaceutical Benefits Scheme or the National Immunisation Program.
Date:   Nov 2006
Title:   Listing of Herceptin on the PBS
Publisher:   Australian Government Department of Health and Ageing
Description:   The Government has accepted a recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) to list the drug trastuzumab (Herceptin®) on the Pharmaceutical Benefits Scheme (PBS).
Date:   Oct 2006
Title:   Risperidone (Risperdal) for behavioural disturbances in dementia
Publisher:   Australian Prescriber
Description:   Risperidone has been PBS-listed as an authority item for behavioural disturbances characterised by psychotic symptoms and aggression in patients with dementia where non-pharmacological methods have been unsuccessful.
Date:   Jun 2005
Title:   Oral isotretinoin
Publisher:   Australian Prescriber
Description:   Oral isotretinoin is listed on the Australian Pharmaceutical Benefits Scheme for patients with severe cystic acne that has failed to respond adequately to other therapy. A single course of isotretinoin induces a long-term remission in over 80% of these patients.
Date:   Jun 2005
Title:   Underneath the RADAR: moxifloxacin
Publisher:   Australian Prescriber
Description:   The quinolone antibiotic moxifloxacin has been listed on the Pharmaceutical Benefits Scheme (PBS), for the oral treatment of community-acquired pneumonia in adults and children over 12 years old who have immediate hypersensitivity to penicillin. This new listing extends the number of patients who can be treated with moxifloxacin.
Date:   Dec 2003
Title:   Your questions to the PBAC. Availability of bulking and osmotic laxative agents as pharmaceutical benefits
Publisher:   Australian Prescriber
Description:   The PBAC is reluctant to recommend laxative products for listing on the PBS and considers that other measures such as modification of diet can be used in the treatment of constipation in most patients.
Date:   Apr 2003
Title:   New listing cuts the costs of leukaemia drug - myDr.com.au
Publisher:   myDr
Description:   A broader Pharmaceutical Benefits Scheme listing for Glivec, a once-daily capsule for the treatment of chronic myeloid leukaemia, means more patients can afford the breakthrough treatment.
Date:   Sep 2002

Results 1 to 19 displayed.